Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)
暂无分享,去创建一个
Robert C. Hendel | Darcy L. DiFede | Joshua M. Hare | Eduard Ghersin | John J. Byrnes | Raul D. Mitrani | R. Hendel | Mauricio G. Cohen | A. Heldman | A. Landin | E. Ghersin | J. Hare | R. Mitrani | J. Byrnes | Angela C. Rieger | Victoria Florea | Marietsy V. Pujol | M. Lowery | Makoto Natsumeda | Alan W. Heldman | Samuel Golpanian | Makoto Natsumeda | Aisha Khan | Victoria Florea | Jill El-Khorazaty | Monisha N. Banerjee | Bryon A. Tompkins | Ivonne H. Schulman | Ana Marie Landin | Muzammil Mushtaq | Maureen H. Lowery | Krystalenia Valasaki | Roberto Miki | Cindy Delgado | Fouad Abuzeid | Mayra Vidro-Casiano | Russell G. Saltzman | Daniel DaFonseca | Lina V. Caceres | Kevin N. Ramdas | Adam Mendizabal | K. Ramdas | Aisha Khan | I. Schulman | Roberto A. Miki | Samuel Golpanian | Krystalenia Valasaki | Cindy Delgado | Bryon A Tompkins | Mayra Vidro-Casiano | Darcy L Difede | J. El-Khorazaty | Fouad Abuzeid | R. Saltzman | A. Mendizabal | Muzammil Mushtaq | Daniel DaFonseca | Angela Castellanos Rieger
[1] M. Zviman,et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. , 2009, European heart journal.
[2] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[3] J. Gorman,et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. , 2009, The Annals of thoracic surgery.
[4] Joshua M Hare,et al. Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue. , 2016, Physiological reviews.
[5] Marcus F Stoddard,et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial , 2011, The Lancet.
[6] Darcy L. DiFede,et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. , 2014, JAMA.
[7] Richard T. Lee,et al. Cardiomyocyte Regeneration: A Consensus Statement. , 2017, Circulation.
[8] Peter A. Altman,et al. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi , 2011, American heart journal.
[9] B. Gersh,et al. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) study , 2017, European journal of heart failure.
[10] J. Kastrup,et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). , 2015, European heart journal.
[11] B. Gersh. Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina , 2012 .
[12] B. Gersh,et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial , 2016, European heart journal.
[13] M. Sever,et al. Effects of Transendocardial CD34+ Cell Transplantation in Patients With Ischemic Cardiomyopathy , 2014, Circulation. Cardiovascular interventions.
[14] G. Lamas,et al. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. , 1989, The American journal of cardiology.
[15] A. Quyyumi,et al. PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. , 2014, Circulation research.
[16] Daniel Berman,et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial , 2012, The Lancet.
[17] William Wijns,et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. , 2013, Journal of the American College of Cardiology.
[18] Peter A. Altman,et al. Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally?: An Analysis From the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) Randomized Trial , 2014, Circulation research.
[19] R. Hendel,et al. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. , 2017, Journal of the American College of Cardiology.
[20] B. Gersh,et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. , 2011, American heart journal.
[21] R. Virmani,et al. A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. , 2007, European heart journal.
[22] Lawrence Buja,et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. , 2008, Journal of molecular and cellular cardiology.
[23] Dejian Lai,et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. , 2012, JAMA.
[24] Joshua M Hare,et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.
[25] Peter A. Altman,et al. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study). , 2007, American heart journal.
[26] Henry R. Halperin,et al. Contrast-Enhanced Multidetector Computed Tomography Viability Imaging After Myocardial Infarction: Characterization of Myocyte Death, Microvascular Obstruction, and Chronic Scar , 2006, Circulation.
[27] A. Quyyumi,et al. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction , 2008, Basic Research in Cardiology.
[28] A. Heldman,et al. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.
[29] Garth M. Beache,et al. Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: The SCIPIO Trial Surgical Aspects and Interim Analysis of Myocardial Function and Viability by Magnetic Resonance , 2012, Circulation.
[30] Peter A. Altman,et al. Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy: Functional Recovery and Reverse Remodeling , 2011, Circulation research.
[31] Yi Zheng,et al. A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. , 2015, Circulation research.